Intended for US audiences only
DANYELZA is a humanized GD2-binding immunotherapy that targets neuroblastoma tumor cells that have GD2 on their cell surface as well as other cells in the body such as nerve cells, pain fibers, and some types of skin cells called melanocytes. The binding to cells can cause side effects such as pain, which can be severe. DANYELZA, in combination with GM-CSF , helps the body’s immune system fight the cancer.
DANYELZA attaches to a sensor on the cancer cell
DANYELZA triggers signaling processes that tell the immune system to attack the cancer cell
The body’s cells kill the cancer cell
DANYELZA may offer your family another treatment option
What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:
DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:
DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.
What is the most important information I should know about DANYELZA?
DANYELZA may cause serious side effects, including:
DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:
DANYELZA is approved based on two clinical studies that looked at reducing tumor size. DANYELZA is still being studied to confirm the study results and the clinical benefit of treatment.